Publications

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

Data from this study demonstrated efficacy of ixekizumab in both mild-to-moderate and severe plaque PsO. Improvement in skin lesions was observed as early as 2 weeks, with progressive enhancement of treatment response through 52 weeks. Patients with moderate plaque PsO (PASI <10) treated with ixekizumab achieved superior PASI 75/90 responses at most timepoints and higher PASI 100 rates at al timepoints compared with those with severe disease (PASI ≥10), along with consistently lower absolute PASI values at equivalent response thresholds.